Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca And Sanofi March Ahead With Positive Phase III RSV Data

MELODY Data Music To Companies’ Ears

Executive Summary

AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.

You may also be interested in...



EU To Sue AstraZeneca Over Vaccine Delivery: Can Either Side Win?

The legal challenge is risky for the European Commission, with AZ’s contract only binding it to make ‘best reasonable efforts’ to deliver vaccines to schedule.

Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion

Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.

Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine

Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel